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Background: This study aimed to determine whether calcium gluconate exerts protective effects on osteoarthritis
(OA) induced by anterior cruciate ligament (ACL) transection and partial medial meniscectomy.
Methods: Calcium gluconate was administered by mouth daily for 84 days to male ACL transected and partial
medial meniscectomized Sprague–Dawley rats 1 week after operation.
Results: Eighty-four days of treatment with 50 mg/kg calcium gluconate led to a lower degree of articular stiffness
and cartilage damage compared to the OA control, possibly through inhibition of overexpressed cyclooxygenase
(COX)-2 and related chondrocyte apoptosis. Similar favorable effects on stiffness and cartilage were detected in
calcium gluconate-administered rats. Additionally, calcium gluconate increased 5-bromo-2′-deoxyuridine (BrdU)
uptake based on observation of BrdU-immunoreactive cells on both the femur and tibia articular surface cartilages
84 days after intra-joint treatment with calcium gluconate.
Conclusions: Taken together, our results demonstrate that calcium gluconate has a protective effect against OA
through inhibition of COX-2 and related chondrocyte apoptosis.
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Osteoarthritis (OA) is characterized by changes in the
structure and function of the articulation. OA is a de-
generative process that takes place in the articular cartil-
age [1], which has a highly limited capacity to regenerate
and repair due to its avascular nature. Chondrocytes are
a pivotal component of the pathogenesis of OA. Under
normal conditions, the synthetic and catabolic activities
of chondrocytes are balanced to maintain the integrity of
articular cartilage in vivo. Stimuli, such as nitric oxide,
prostaglandin E2, Fas ligand, and tumor necrosis factor-
α [2-5], disrupt the ability of chondrocytes to maintain* Correspondence: gucci200@hanmail.net; gksxntk@dhu.ac.kr
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unless otherwise stated.the integrity of articular cartilage, leading ultimately to
apoptosis. Apoptosis of chondrocytes was initially re-
ported in relation to the differentiation of hypertrophic
chondrocytes and ossification of the growth plate [6,7].
Thus, modulation of the mechanism(s) of apoptosis-
inducing factors is considered a novel strategy for the
treatment of OA [8].
Caspase-3 is one of the key mediators of apoptosis, as
it is either partially or totally responsible for the proteo-
lytic cleavage of many key proteins, such as nuclear en-
zyme poly-ADP ribose polymerase (PARP) [9]. PARP is a
representative target molecule of caspase-3 that facili-
tates activation of the DNA repair system by caspase-
mediated cleavage [10,11].
Prostaglandin is involved in the pathogenesis of OA
[3]. It is derived primarily from cyclooxygenase (COX)-2
and plays a role as a key mediator of the inflammation
and pain associated with OA. Conversely, inhibition ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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steroidal anti-inflammatory drugs (NSAIDs) and COX-2
inhibitors ameliorate OA symptoms [12,13].
Accumulating evidence suggests that calcium salts
possess anti-inflammatory activity. Calcium chloride has
been advocated for the treatment of urticaria, acute
edema, pruritis, and erythema [14]; calcium carbonate
and calcium gluconate have been used for the treatment
of insect stings [15], and calcium hydroxide has been
used to suppress periapical inflammation in dental prac-
tice [16]. Thus, we examined whether calcium gluconate
exerts protective effects on OA induced by anterior cru-




Thirty-six male Sprague–Dawley rats (160–180 g,
6 weeks old upon receipt, SLC, Osaka, Japan) were
housed (3–4 per cage) and allowed to acclimate 9 days
before use (light/dark cycle, 12 h). A normal rodent pel-
let diet and water were supplied ad libitum throughout
all experiments, including during acclimatization. All an-
imals were fasted overnight prior to sacrifice (approxi-
mately 18 h with ad libitum access to water) and treated
according to the Guide for the Care and Use of Labora-
tory Animals of the Institute of Laboratory Animal Re-
sources, Commission on Life Science, 1996 National
Research Council, Washington D.C.
Preparations and administration of test materials
In sham control rats, distilled water (5 ml/kg) was orally
administered daily. In OA control rats, animals were orally
administered 1 ml/kg distilled water in the absence of cal-
cium gluconate. As a reference control, 2 mg/kg diclofenac
sodium (Sigma, St. Louis, MO, USA) dissolved in saline
was administered subcutaneously daily for 84 days begin-
ning 1 week after induction of OA. Calcium gluconate (25,
50, and 100 mg/kg) was dissolved in distilled water and or-
ally administered daily for 84 days (5 ml/kg) to OA rats
that underwent ACL transection and partial medial men-
iscectomy, beginning 1 week after the operation.
Induction of OA
Rats were anesthetized with an intraperitoneal injection
(25 mg/kg) of Zoletile mixture (Zoletile 50, Virbac Lab.,
Carros Cedex, France). The surgery was carried out ac-
cording to the method of Kamekura et al. [17]. Briefly,
the OA treatment group underwent open surgery involv-
ing ACL transection and partial medial meniscectomy
via an incision in the medial aspect of the joint capsule,
anterior to the medial collateral ligament. The operation
was performed using a 15° 5-mm blade micro-surgical
knife, micro-iris scissors, and micro-corneal suturingforceps and #11 and #15 blades. Following surgery, sa-
line was used for washing tissue debris; the incision was
closed in two layers. The joint capsule was sutured inde-
pendently from peripheral tissues using dissolvable 5–0
Vicryl sutures, and the skin was closed by interrupted
sutures using silk. This treatment was used to induce
OA pathogenesis and referred to as operated-induced
sides. Conversely, the right (non-operated intact side)
knee joint was used as the contralateral treatment. The
second group of rats underwent a sham operation in
which a similar incision in the joint capsule was made,
but ACL transection and partial medial meniscectomy
were not performed. Only the left knees of sham animals
were used as controls for disease progression.
Evaluation of clinical symptom changes
Body weights were measured weekly from the start of
calcium gluconate treatment until sacrifice with an auto-
matic electronic balance (Precisa Instrument, Dietikon,
Switzerland). In addition, body weight gain during
12 weeks of observation (following calcium gluconate or
diclofenac sodium treatments) was calculated. The thick-
ness of OA in the hind knee (right side) was measured
using an electronic digital caliper (Mitutoyo, Kawasaki,
Japan) and recorded weekly following treatment. OA-
operated knees in all animals were dissected from the
coxofemoral region to the ankle, leaving the articular
capsule intact. After dissection, the maximum extension
angle of each knee was measured, with 0° corresponding
to the maximum possible extension.
Histology and evaluation
Portions of the knee joints were sampled in a manner
that preserved the joint capsule and fixed in 10%
neutral-buffered formalin. After 5 days of fixation, sec-
tions were decalcified using a decalcifying solution
(24.4% formic acid, 0.5 N sodium hydroxide) for 5 days
(mixed decalcifying solution was exchanged daily for
5 days). Median joint parts were then longitudinally
trimmed and embedded in paraffin, sectioned (3–4 μm),
and stained with hematoxylin and eosin (H&E) or Safra-
nin O for cartilage. Articular cartilage injuries found in
the knees of rats were evaluated and recorded using the
Mankin score, as referred to by Armstrong et al. [18]
and Lovász et al. [19]. Tibial and femoral articular cartil-
age thicknesses were measured by means of histomor-
phometric analyses in longitudinally trimmed samples at
the micrometer level using a digital image analyzer
(DMI-300, DMI, Daegu, Korea).
BrdU uptake
Proliferating cells were labeled by means of an intraperi-
toneal injection of 5-bromo-2′-deoxyuridine (BrdU).
One hour prior to injection of diclofenac sodium or oral
Table 1 Knee thicknesses after joint capsule exposure
and maximum extensor angles detected at sacrifice
Groups Knee thicknesses
after joint capsule




Sham 7.72 ± 0.27 31.63 ± 3.46
OA 9.76 ± 0.60a 66.88 ± 7.47a
Diclofenac 9.16 ± 0.28ac 47.13 ± 7.26ac
Calcium gluconate-treated
100 mg/kg 8.96 ± 0.40ac 39.50 ± 6.52bc
50 mg/kg 9.16 ± 0.20ac 47.38 ± 7.48ac
25 mg/kg 9.52 ± 0.64a 66.75 ± 10.33a
After 84 days of continuous oral treatment of calcium gluconate or
subcutaneous treatment of diclofenac sodium in OA rats. Values are expressed
as mean ± SD of eight rats. OA, osteoarthritis; ap < 0.01 and bp < 0.05 compared
with sham control; cp < 0.01 compared with OA control.
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ment), rats received intraperitoneal injections of BrdU
(MP Biomedicals, Solon, OH, USA; 50 mg/kg), in a vol-
ume of 2 ml/kg, dissolved in saline; the animals were
sacrificed 72 h later. BrdU uptake was evaluated by immu-
nohistochemistry using an anti-BrdU antibody.
Immunohistochemical determination of apoptosis
To assess the effects of calcium gluconate on chondro-
cyte apoptosis within rat knees, the number of caspase-
3-, PARP- and COX-2-positive cells were determined
using immunohistochemistry. Fixed tissues were pre-
pared, deparaffinized, and sectioned as described above
histology part. After blocking for 1 h, sections were in-
cubated with the appropriate primary antibody over-
night at 4°C. They were incubated for 1 h with a
biotinylated universal secondary antibody (Vector Lab.
Inc., Burlingame, CA, USA; dilution 1:50) and then were
incubated for 1 h with the ABC reagents (Vectastain
Elite ABC kit, Vector Lab. Inc.; dilution 1:50). They
were incubated in peroxidase substrate reagents (Vector
Lab. Inc.), counterstained with Mayer's hematoxylin so-
lution and observed under a light microscope (Nikon,
Tokyo, Japan).
Statistical analyses
Multiple comparison tests for the dosage groups were
conducted. Data were subjected to one-way analysis of
variance (ANOVA) or the non-parametric Kruskal–Wallis
H comparison test, according to the results of the variance
homogeneity Levene test. Statistical analyses were con-
ducted using SPSS for Windows (Release 12.0 K, SPSS
Inc., Chicago, IL, USA).Figure 1 Body weight changes and knee thickness of OA rats. (A) Bod
gluconate. (B) Knee thickness in OA-induced joints was significantly (p < 0.0
compared with that in OA controls. Values represent the means ± standard
1 day before start of treatment; AT, start day of administration; AS, at sacrifi
and sacrifice.Results
Knee thickness was increased significantly in OA-
operated knees compared with sham control knees fol-
lowing treatment for 84 days. However, this increase in
OA-induced knee thickness was decreased significantly
compared with that in OA control knees 21 days after
treatment with diclofenac sodium and 50 and 100 mg/kg
calcium gluconate (Figure 1B).
Knee thickness of OA-operated joint capsule was in-
creased significantly in all OA-induced groups compared
with that in sham control rats. In contrast, diclofenac
sodium and 50 and 100 mg/kg calcium gluconate treat-
ment reduced knee thicknesses compared with those in
OA controls (Table 1). The maximum extensor angles ofy weight changes in OA rats following treatment with calcium
1 or p < 0.05; arrow) decreased in calcium gluconate-treated rats
deviation (SD) of eight rats. OA, osteoarthritis; AO, operation day; BT,
ce. All animals were fasted overnight prior to the start of administration
Table 2 Mankin scores detected in femur and tibia at sacrifice
Groups Femur Tibia
Surface Hypocellularity Clones Safranin O Totala Surface Hypocellularity Clones Safranin O Totala
Controls
Sham 0.25 ± 0.46 0.25 ± 0.46 0.00 ± 0.00 0.38 ± 0.52 0.88 ± 0.64 0.38 ± 0.52 0.38 ± 0.52 0.13 ± 0.35 0.38 ± 0.52 1.25 ± 1.39
OA 2.75 ± 0.46b 2.50 ± 0.53a 2.25 ± 0.89b 2.38 ± 0.52b 9.88 ± 1.13b 2.63 ± 0.52b 2.38 ± 0.52b 2.63 ± 0.52b 2.13 ± 0.83b 9.75 ± 1.04b
Diclofenac 2.00 ± 0.53cd 1.63 ± 0.52bd 2.25 ± 0.71b 1.38 ± 0.52bd 7.25 ± 1.39bd 1.88 ± 0.64be 1.63 ± 0.74be 1.75 ± 0.46bd 1.38 ± 0.74ce 6.63 ± 1.19bd
Calcium gluconate treated
100 mg/kg 1.38 ± 0.74bd 1.25 ± 0.89bd 1.50 ± 0.76b 0.63 ± 0.52d 4.75 ± 1.98bd 1.25 ± 0.71bd 1.00 ± 0.76d 1.00 ± 0.76bd 1.25 ± 0.71ce 4.50 ± 2.20bd
50 mg/kg 2.00 ± 0.76be 1.50 ± 0.76bd 1.75 ± 0.46b 2.13 ± 0.35b 7.38 ± 1.77bd 2.00 ± 0.76be 1.63 ± 0.52be 1.50 ± 0.53bd 1.38 ± 0.74ce 6.50 ± 2.20bd
25 mg/kg 2.38 ± 0.74b 2.38 ± 0.52b 2.50 ± 0.53b 2.50 ± 0.76b 9.75 ± 1.16b 2.75 ± 0.46b 2.38 ± 0.74b 2.13 ± 0.64b 1.88 ± 0.83 9.13 ± 2.30b
After 84 days of continuous oral treatment of calcium gluconate or subcutaneous treatment of diclofenac sodium in OA rats. Values are expressed as mean ± SD of eight rats, scores (Table 1). OA, osteoarthritis. aTotal



















Table 3 Histomorphometrical scores detected at sacrifice
Groups Thickness of articular cartilages
Femur Tibia
Controls
Sham 570.69 ± 63.08 887.40 ± 75.03
OA 317.82 ± 77.79a 354.80 ± 46.41a
Diclofenac 472.56 ± 63.04ab 486.90 ± 41.78ab
Calcium gluconate treated
100 mg/kg 574.06 ± 55.77b 689.43 ± 93.78ab
50 mg/kg 471.21 ± 47.69ab 482.43 ± 65.10ab
25 mg/kg 335.92 ± 40.20a 356.14 ± 52.71a
After 84 days continuous oral treatment of calcium gluconate or subcutaneous
treatment of diclofenac sodium in OA rats. Values are expressed as mean ± SD
of eight rats, μm; OA, osteoarthritis. ap < 0.01 compared with sham control;
bp < 0.01 compared with OA control.
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nificantly greater (111.46%) compared with those in
sham controls. However, these angles were significantly
decreased by treatment with diclofenac sodium and 25,
50, and 100 mg/kg calcium gluconate compared with
those in OA controls (Table 1).
Total Mankin scores of induced femur and tibia articu-
lar cartilage in OA controls were significantly increased
compared with those of the sham control; the scores in
diclofenac sodium- and calcium gluconate (50 and
100 mg/kg)-treated groups were significantly decreased
as compared with those in OA control, respectively
(Table 2).
OA-induced femur and tibia articular cartilage thick-
nesses decreased significantly in OA controls compared
with sham controls but were significantly increased in
the groups treated with diclofenac sodium and 50 and
100 mg/kg calcium gluconate, compared with those in
the OA controls (Table 3 and Figure 2).
With regard to the effects on cell proliferation, OA con-
trols showed little or no BrdU staining in both the tibia
and femur articular cartilage compared with sham con-
trols. However, these decreases in BrdU-immunoreactive
cells were significantly inhibited by treatment with 50 and
100 mg/kg calcium gluconate compared with OA controls
(Figure 3).
Caspase-3-immunoreactive cell numbers in OA-induced
femur articular cartilage changed by 546.07% compared
with those in the sham control, specifically, −34.09%,
−62.26%, −28.52%, and −5.22% in the groups treated
with diclofenac sodium and calcium gluconate (100, 50,
and 25 mg/kg), respectively, compared with those in OA
controls. Caspase-3-immunoreactive cell numbers in tibia
articular cartilage changed by 452.83% compared with those
in the sham control, specifically, −43.17%, −27.87%, −41.81%,
and −5.46% in the groups treated with diclofenac sodium
and calcium gluconate (100, 50, and 25 mg/kg), respectively,compared with those in the OA control (Figure 3). PARP-
immunoreactive cell numbers in OA-induced femur ar-
ticular cartilage thickness of OA controls changed by
485.37% compared with those in the sham control, spe-
cifically, −42.92%, −65.63%, −42.92%, and −0.42% in the
groups treated with diclofenac sodium and calcium gluco-
nate (100, 50, and 25 mg/kg), respectively, compared with
those in the OA control. PARP-immunoreactive cell num-
bers in OA-induced tibia articular cartilage changed by
246.09% compared with those in the sham control, specif-
ically, −41.21%, −59.30%, −38.19%, and −0.25% in the
groups treated with diclofenac sodium and calcium glu-
conate (100, 50, and 25 mg/kg), respectively, compared
with those in the OA control (Figure 3). COX-2-
immunoreactive cell numbers in OA-induced femur ar-
ticular cartilage thickness of OA controls changed by
287.86% compared with the sham control; specifically,
−54.51%, −58.01%, −29.28%, and −0.92% in the groups
treated with diclofenac sodium and calcium gluconate
(100, 50, and 25 mg/kg), respectively, compared with
those in the OA control. COX-2-immunoreactive cell
numbers in OA-induced tibia articular cartilage chan-
ged by 253.90% compared with those in sham controls,
specifically, −62.02%, −67.34%, −27.89%, and −2.02% in
the groups treated with diclofenac sodium and calcium
gluconate (100, 50, and 25 mg/kg), respectively, com-
pared with those in the OA control (Figure 3).
Discussion
In the present study, no meaningful changes in body
weight and/or weight gain were detected in the groups
treated with diclofenac sodium or calcium gluconate
compared with the sham and OA controls. Changes in
body weight and weight gain in all rats were within the
normal range of age-matched rats. OA, also known as a
degenerative joint disease, is a type of chronic inflamma-
tory disease. Cartilage damage in OA can lead to edema-
tous changes on the surrounding tissues and a marked
increase in the thickness of affected joints [20]. The
thickness of operated knees was higher compared with
those of sham controls, while these changes were mark-
edly inhibited by treatment with calcium gluconate (50
and 100 mg/kg). The effects of calcium gluconate treat-
ment are likely attributable to its anti-inflammatory
properties [15,13].
Increases in maximum extension angles in induced
knees were markedly inhibited by 50 and 100 mg/kg cal-
cium gluconate or diclofenac sodium; direct evidence
suggests that >50 mg/kg calcium gluconate ameliorates
the progression of OA. Joint stiffness was evaluated by
measuring the maximum extension joint angle, in which
0° is considered the maximum extension.
The Mankin scoring system is a commonly used histo-
pathological method of detecting articular cartilage injuries
Figure 2 Histopathological observations of the tibial and femoral articular cartilage. Of sham controls (A, B), OA controls (C, D), and the
diclofenac sodium (E, F) or calcium gluconate 100 mg/kg (G, H), 50 mg/kg (I, J), and 25 mg/kg (K, L)-treated groups. Histopathological changes
were markedly inhibited by calcium gluconate. Arrows indicate the thickness of tibia or femur articular cartilage; OA, osteoarthritis; gaps indicate
the intra-joint space between the articular surface of the tibia and femur. Scale bar = 80 μm.
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calcium gluconate treatment of both the tibia and femur.
Therefore, >50 mg/kg calcium gluconate ameliorated OA-
associated cartilage damage. In addition, calcium gluconatetreatment (>50 mg/kg) reversed the decreased articular car-
tilage thickness, as did diclofenac sodium.
Numbers of BrdU-immunoreactive cells were de-
creased significantly in both the femur and tibia surface
Figure 3 BrdU, caspase-3, PARP, and COX-2-immunoreative cells in the tibial and femoral articular cartilage. Of sham controls (A, B), OA
controls (C, D), and the diclofenac sodium (E, F) or calcium gluconate 100 mg/kg (G, H), 50 mg/kg (I, J) and 25 mg/kg (K, L)-treated groups.
Changes in the numbers of immunoreactive cells were significantly (p < 0.01 or p < 0.05) inhibited by treatment with calcium gluconate
compared with OA controls. Dark brown staining indicates immunoreactive cells; OA, osteoarthritis. Scale bar = 80 μm.
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hibition of chondrocyte proliferation. However, these
changes in the numbers of BrdU-immunoreactive cells
were inhibited by treatment with 50 and 100 mg/kg cal-
cium gluconate, unlike diclofenac sodium treatment,
after which no marked changes in numbers of BrdU-
immunoreactive cells were detected. The degree of facili-
tation of chondrocyte proliferation induced by calcium
gluconate differed from that of the diclofenac sodium
treatment; therefore, further studies are needed to better
understand the mechanism of action of calcium gluco-
nate. Among the methods of evaluating cell proliferation
in histological sections, BrdU immunohistochemistry is
the most preferable. In addition, BrdU uptake can be
used to evaluate chondrocyte proliferation in OA cartil-
age [22].
Decreases in the numbers of caspase-3- and PARP-
immunoreactive cells among femur and tibia chondro-
cytes indicate that 50 mg/kg calcium gluconate protects
chondrocytes against apoptosis. In addition, the decrease
in COX-2-immunoreactivity in the femur and tibia articu-
lar cartilage suggests that 50 mg/kg calcium gluconate in-
hibits COX-2 overexpression. Indeed, it is hypothesized
that calcium gluconate exerts anti-inflammatory effects
mediated by inhibition of COX-2 expression and related
chondrocyte apoptosis. Consequently, calcium gluconate
exerted favorable protective effects against OA similar
to those of diclofenac sodium. Inhibition of COX-2 and
prostaglandin synthesis by traditional NSAIDs and
COX-2 inhibitors provides effective relief of OA symp-
toms [12]. These results indicate that calcium gluconate
ameliorates OA via COX-2 inhibition, leading to repressionof chondrocyte apoptosis. Increasing evidence suggests the
involvement of chondrocyte apoptosis in the pathogenesis
of OA [2,8]. Ou et al. reported that celecoxib (a selective
COX-2 inhibitor) diminishes OA by repressing chondro-
cyte apoptosis [13]. In addition, inhibition of COX-2 can
reduce the caspase-3 level and chondrocyte death [16].
In the present study, obtaining X-ray images of rats is
difficult due to their small size; in general, X-ray analysis
and radiological scoring is suitable for larger animals,
such as rabbits. Although we identified amelioration by
calcium gluconate of OA in rats by histological analysis,
further studies using high-resolution X-ray equipment
are required to clarify the effect of calcium gluconate on
OA.
Taken together, our results indicate that calcium glu-
conate ameliorates the articular stiffness and cartilage
damage associated with OA. Our results suggest that
doses of calcium gluconate >50 mg/kg have a protective
effect against OA through inhibition of COX-2 overex-
pression and related chondrocyte apoptosis.
Conclusions
The results obtained in this study suggest that oral ad-
ministration of calcium gluconate (>50 mg/kg) for 84
consecutive days ameliorates articular stiffness and car-
tilage damage compared to OA controls, possibly by
inhibiting overexpression of COX-2, a key enzyme in
prostaglandin synthesis and related chondrocyte apop-
tosis. Similar favorable effects on OA-mediated stiffness
and cartilage loss were detected in rats that received
50 mg/kg calcium gluconate orally. Moreover, calcium
gluconate increased BrdU uptake, based on the numbers
Kang et al. Journal of Orthopaedic Surgery and Research 2014, 9:14 Page 8 of 8
http://www.josr-online.com/content/9/1/14of BrdU-immunoreactive cells in both the femur and
tibia articular cartilage at 84 days after intra-joint treat-
ment with calcium gluconate.
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